BioDelivery Files BEMA Fentanyl NDA For Breakthrough Cancer Pain
This article was originally published in The Pink Sheet Daily
Executive Summary
Commercial partner Meda has 450 specialty reps at the ready for late 2008 launch of the fast-dissolving buccal pain therapy, BDSI CEO Sirgo says.